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Abstract
Background: The relationship between admission low-density lipoprotein (LDL) levels and
long-term outcomes has not been established in patients with acute coronary syndrome. We
tested the hypothesis that patients who develop non-ST segment elevation myocardial infarc-
tion (NSTEMI) despite low LDL have a worse cardiovascular outcome in the long term.
Methods: Patients admitted with NSTEMI between 1 January 1997 and 31 December 2000
and with fasting lipid profiles measured within 24 hours of admission were selected for
analysis. Baseline characteristics and 3-year all-cause mortality were compared between the
patients with LDL above and below the median. Multivariate analysis was used to determine
the predictors of all-cause mortality, and adjusted survival was analyzed using the Cox propor-
tional hazard model.
Results: Of the total of 517 patients, 264 had LDL £ 105 mg/dL and 253 had LDL > 105 mg/dL.
There was no difference in age, gender, severity of coronary artery disease, and left ventricular
ejection fraction between the 2 groups. Thirty-six percent of patients with LDL £ 105 mg/dL
and 24% of patients with LDL > 105 mg/dL were on lipid-lowering therapy on admission.
After 3 years, patients with admission LDL £ 105 mg/dL had higher all-cause mortality rate
compared to patients with LDL > 105 mg/dL (14.8% vs. 7.1%, p = 0.005). The higher
all-cause mortality persisted (OR 1.8, 95% CI 1.0–3.5, p = 0.05) even after adjustment for
confounding variables.
Conclusions: In our cohort, lower LDL-cholesterol at admission was associated with de-
creased 3-year survival in patients with NSTEMI. Whether this was a result of current
therapy or a marker for worse baseline characteristics needs to be studied further. (Cardiol J
2009; 16, 3: 227–233)
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Condensed Abstract
We tested the hypothesis that patients who
develop non-ST segment elevation myocardial in-
farction (NSTEMI) despite low low-density lipopro-
tein (LDL) have a worse cardiovascular outcome in
the long term. We studied 517 consecutive patients
with NSTEMI. At 3 years follow-up, patients with
admission LDL below the mean had higher all-
-cause mortality rates compared to patients with
LDL above the mean. Whether this was a result of
current therapy or a marker for worse baseline
characteristics needs to be studied further.
Introduction
Hypercholesterolemia has been shown to be an
independent risk factor for the development of co-
ronary artery disease (CAD) [1–4]. Randomized
controlled trials have demonstrated that lipid lowe-
ring therapy improves all-cause mortality and mor-
bidity in patients with risk factors for, and with es-
tablished CAD [5–12]. However, many patients still
develop atherosclerotic complications despite
being on lipid lowering therapy and/or having target
low lipid profiles. In randomized trials involving
patients with CAD, major adverse cardiac events
(MACE) were noted in 8–22% of patients on lipid
lowering therapy despite achieving target lipid
levels [5–12]. Low cholesterol levels have been
associated with poor prognosis in some cardiac and
non-cardiac disease states. Among congestive heart
failure patients, low low-density lipoprotein (LDL)
has been associated with worse outcomes [14–17].
Other data suggests that hypocholesterolemia is as-
sociated with worse outcome among elderly patients,
cancer patients, HIV patients, and dialysis patients
[18–24]. Although the benefits of statins have been
well demonstrated before, the prognostic value of
admission LDL has not been established in patients
with documented CAD presenting with acute coro-
nary syndrome. We tested the hypothesis that pa-
tients who develop non-ST segment elevation my-
ocardial infarction (NSTEMI) despite low LDL have
a worse outcome in the long term.
Methods
This study was approved and monitored by the
Investigational Review Board of the study hospital.
The study population consisted of consecutive
patients admitted to the Coronary Intensive Care
Unit (CICU) of a tertiary care hospital between
January 1997 and December 2000 with admission
diagnosis of NSTEMI, who had had lipid profile me-
asured within 24 hours of hospital admission. Pa-
tients with lipid profile measured beyond 24 hours
of hospital admission were excluded as the validity
of the plasma lipid levels measured beyond 24 ho-
urs from the onset of myocardial infarction has been
questioned [25–30]. NSTEMI was defined as pa-
tients presenting with chest pain suggestive of
myocardial ischemia, with positive markers of myo-
cardial damage (creatinine kinase-MB or troponin)
and/or electrocardiographic changes other than ST
segment elevation. The diagnosis was made at the
time of admission to the cardiac intensive care unit.
Patients with ST-segment elevation, new onset left
bundle branch block, cardiac arrest, and those not
undergoing coronary angiography during the hospi-
talization were excluded. We included only patients
undergoing angiography, in order to capture pa-
tients who had definite acute coronary syndrome
and coronary artery disease. Fasting lipid profile
including total, LDL, high-density lipoprotein
(HDL) cholesterol, and triglycerides that were
measured in the first 24 hours of admission were
collected. Clinical variables, angiographic results,
and outcomes were obtained from electronic and
written medical records, cardiac catheterization lab
data forms, and the CICU database. The CICU
database is a prospective registry of every admission
to the 16-bed CICU. The database includes 300
discrete data elements prospectively recorded on
case report forms by trained research assistants and
updated annually. Six-month clinical outcomes were
collected using chart review. All-cause mortality
data was verified with the Social Security Death
Certificate Registries with three-year follow-up.
Patients were divided into two groups based
on whether they had LDL level below or above the
median LDL. The primary endpoint was three-year
all-cause mortality. The secondary endpoint was
MACE at 6 months. MACE was defined as all-cau-
se mortality, non-fatal myocardial infarction, percu-
taneous coronary intervention (PCI), or coronary
artery bypass grafting (CABG) at follow-up.
Statistical analysis
Baseline demographic and clinical characteri-
stics were compared between groups using Stu-
dent’s t-test for continuous variables and c2 analysis
for categorical variables. The all-cause mortality
between the groups was initially analyzed with pair-
wise comparisons. Cox proportional hazard analysis
was used to determine the independent predictors
of all-cause mortality. In addition, adjusted survi-
val curves were constructed and compared with
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Cox-regression survival analysis. Adjustment was
done for both baseline variables with unequal distri-
bution (gender, race, prior myocardial infarction, hy-
pertension, diabetes, lipid-lowering therapy, prior
aspirin, beta-blockers, diastolic blood pressure, and
admission HDL level). A p-value £ 0.05 was consi-
dered significant for all analyses. Statistical analy-
sis was done using SPSS 11.5.
Results
Between 1 January 1997 and 31 December
2000, of the 836 patients admitted with a diagnosis
of NSTEMI, 517 patients had fasting lipid profiles
measured within 24 hours of admission. The me-
dian LDL level was 105 mg/dL. Two hundred and
sixty-four patients (51%) had LDL £ 105 mg/dL and
253 patients (49%) had LDL > 105 mg/dL.
Table 1 compares the baseline and demogra-
phic characteristics of the 2 groups. There were
no differences in age and gender between the
2 groups. However, patients with lower LDL were
more often: Caucasians, on lipid lowering therapy,
and had prior history of hypertension, diabetes,
peripheral vascular disease, and myocardial infar-
ction.
Table 2 shows the mean admission lipid profi-
le and peak cardiac enzymes between the 2 groups.
Patients who had admission LDL £ 105 mg/dL also
had lower mean HDL cholesterol levels but the
mean triglyceride levels were comparable. Infarct
size as estimated by peak creatinine kinase and tro-
ponin were comparable between the 2 groups.
Table 3 compares the in-hospital management
of these patients. There was no difference in the
rate of balloon pump use or mechanical ventilation
Table 1. Baseline characteristics.
Variable LDL £ 105 mg/dl LDL > 105 mg/dL p
(n = 264)  (n = 253)
Mean age ± SD (years) 63 ± 13 62 ± 12 0.2
White (%) 181 (67%) 138 (55%) 0.006
Female (%) 102 (39%) 107 (42%) 0.4
Previous myocardial infarction (%) 88 (33%) 63 (25%) 0.035
Chronic heart failure (%) 36 (14%) 28 (11%) 0.4
Diabetes (%) 99 (38%) 69 (27%) 0.013
Hypertension (%) 189 (72%) 154 (61%) 0.01
Peripheral vascular disease 25 (9.5%) 11 (4.3%) 0.022
Lipid lowering therapy (%) 87 (36%) 53 (24%) 0.005
Aspirin (%) 119 (45%) 94 (37%) 0.06
Beta-blocker (%) 104 (40%) 71 (29%) 0.009
ACE inhibitor (%) 76 (29%) 68 (27%) 0.6
Admission mean SBP ± SD [mm Hg] 136±28 136±26 0.9
Admission mean DBP ± SD [mm Hg] 70±17 73±16 0.03
Admission mean pulse ± SD [bpm] 77±18 75±18 0.1
SD — standard deviation; ACE — angiotensin converting enzyme
Table 2. Admission lipid profile and peak cardiac enzymes.
Variable LDL £ 105 mg/dL LDL > 105 mg/dL p
(n=264)  (n = 253)
Total cholesterol ± SD [mg/dL] 152±30 220±44 £ 0.001
LDL-cholesterol ± SD [mg/dL] 79±19 144±38 £ 0.001
HDL-cholesterol ± SD [mg/dL] 41±14 47±14 £ 0.001
Triglyceride ± SD [mg/dL] 160±116 150±87 0.25
Peak C-reactive protein ± SD [mg/dL] 770±1624 745±1016 0.8
Peak troponin ± SD [ng/dL] 95±147 81±129 0.25
SD — standard deviation; LDL — low density lipoprotein; HDL — high density lipoprotein
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use. Patients with LDL £ 105 mg/dL had slightly
lower mean diastolic blood pressure on admission,
but comparable mean systolic blood pressure and
pulse rate.
All patients included in this analysis underwent
coronary angiography. Table 4 compares the angio-
graphy and revascularization data between these
groups. There were no significant differences in the
severity of coronary artery disease. Left ventricu-
lar (LV) function estimates with either ventriculo-
graphy or echocardiography were obtained in all pa-
tients. The degree of LV dysfunction between the
groups was comparable. In addition, revasculariza-
tion therapy and modalities were not different be-
tween the 2 groups.
There were no significant differences in major
adverse cardiac events between the 2 groups at
6 months, as shown in Table 5. However, patients
with LDL £ 105 mg/dL had a statistically signifi-
cant higher all-cause mortality at 6 months (10% vs.
5%, p = 0.03).
At three years, patients with admission LDL
£ 105 mg/dL had higher all-cause mortality rates
compared to patients with LDL > 105 mg/dL
Table 3. Hospital therapies.
Variable LDL £ 105 mg/dL LDL > 105 mg/dL p
(n = 264) (n = 253)
Intra-aortic balloon pump (%) 25 (10) 24 (9) 0.9
Mechanical ventilation (%) 20 (8) 14 (6) 0.3
Table 4. Coronary angiography results and revascularization.
Variable LDL £ 105 mg/dL LDL > 105 mg/dL p
(n = 264) (n = 253)
CAD stenosis (%) 0.8
Non obstructive 25 (9%) 20 (8%)
1 vessel disease 76 (29%) 79 (31%)
2 vessel disease 63 (24%) 63 (25%)
3 vessel disease 101 (38%) 91 (36%)
Left main disease (%) 25 (10%) 17 (7%) 0.2
LVEF (%) 0.8
Normal 137 (52%) 128 (51%)
Mild depressed 56 (21%) 54 (21%)
Mod depressed 48 (18%) 43 (17%)
Severely depressed 23 (9%) 28 (11%)
PCI (%) 142 (54%) 139 (55%) 0.8
CABG (%) 37 (14%) 28 (11%) 0.3
CAD — coronary artery disease; LVEF — left ventricular ejection fraction at the time of angiography; PCI — percutaneous coronary intervention;
CABG — coronary artery bypass grafting
Table 5. Six-month outcomes.
Variable LDL £ 105 mg/dL LDL > 105 mg/dL p
(n = 264)  (n = 253)
Death (%) 26 (10%) 12 (5%) 0.03
Major adverse cardiac events (%) 63 (24%) 54 (21%) 0.5
Myocardial Infarction (%) 19 (7%) 16 (6%) 0.7
Coronary artery bypass grafting (%) 19 (7%) 19 (8%) 0.9
Percutaneous coronary intervention (%) 21 (8%) 26 (10%) 0.4
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(14.8% vs. 7.1%, p = 0.005, odds ratio [OR] 2.3, 95%
confidence interval [CI] 1.3–4.1). This continued to
be significant after adjusting for gender, race, prior
myocardial infarction, hypertension, diabetes, lipid
lowering therapy, prior aspirin, beta-blockers, dia-
stolic blood pressure, and admission HDL level
(OR 2.0, 95% CI 1.1–3.5, p = 0.02). Adjusted 3-year
survival curves are shown in Figure 1.
Discussion
This analysis demonstrates that LDL-choleste-
rol levels of £ 105 mg/dL within 24 hours of admis-
sion are associated with higher long-term all-cause
mortality in patients admitted with NSTEMI. As far
as we are aware, this is the first study to report this
observation in acute coronary syndrome patients.
This finding initially appears paradoxical to current
thinking about lipids and outcomes in patients with
CAD. Elevated cholesterol levels have been shown
to increase the risk of atherosclerotic heart disease,
and its complications and cholesterol lowering has
been shown to reduce cardiovascular events [5–12].
However, it is possible that lower cholesterol le-
vels at the time a myocardial infarction in this pa-
tient population may actually identify patients with
higher long-term all-cause mortality. The 2 popu-
lations of low and high LDL patients are inherently
different. Although we used Cox analysis and
attempted to account for all known different cha-
racteristics between the 2 groups, there could have
been some other variables that we did not account
for that could have resulted in this worse long-term
outcome.
Another explanation for our findings could be
differences in the atherosclerotic disease pattern.
An atherosclerotic complication like myocardial in-
farction is usually the result of multiple factors and
lipid levels is only one of the identified risk factors.
In fact, it has recently been shown that the level of
an inflammatory marker C-reactive protein may be
a better predictor of worse outcome than reduction in
lipid levels after NSTEMI [31]. Seventy-five percent
of the events are still not prevented by aggressive
treatment with statins to achieve LDL cholesterol
levels £ 70 mg/dL [8]. Therefore, there are factors
other than cholesterol levels that confer this risk
in the majority of the patients. It is possible that
patients who have a myocardial infarction in spite
of a low LDL level have other risk factors that are
not readily modifiable. Thus, plaque rupture in the
setting of a low LDL cholesterol levels may signify
more complex atherosclerotic disease in patients
with higher risk of long-term event rates.
An example of a preventative measure that may
be a marker of adverse prognosis at the time of an
event is aspirin therapy. Aspirin use is known to
reduce atherothrombotic complications in patients
with cardiovascular risk factors [32]. However, aspi-
rin use within the prior 7 days of an myocardial in-
farction has been shown to be an adverse progno-
sticator in patients with acute coronary syndromes
[33]. It is believed that if atherothrombosis deve-
lops in spite of aspirin use, this is an indicator of
a more complex plaque morphology conferring hi-
gher clinical risk in these patients.
Epidemiological studies have also shown that
a lower cholesterol level is associated with worse
outcome in patients with established heart failure
[14–17]. The reason for this is not entirely clear
[34]. Similar findings regarding the association of
low serum cholesterol and poor outcome have been
reported for elderly individuals, end-stage renal
failure patients undergoing dialysis, cancer patients,
and individuals with AIDS [18–23]. It is possible that
low LDL may be associated with illnesses other
than cardiovascular disease that lead to higher
all-cause mortality. It has been suggested that
LDL-cholesterol levels acutely decrease more with
larger myocardial infarction within a few days of
Figure 1. Adjusted survival curves: the dotted line re-
presents LDL less than the median and the continuous
line represents LDL above the median. Adjusted for
race, prior myocardial infarction, hypertension, diabe-
tes, lipid lowering therapy, smoking, prior aspirin, beta-
-blockers, diastolic blood pressure, and admission HDL
level. The 3-year adjusted all-cause mortality odds ratio
2.0, 95% confidence interval 1.11–3.5, p = 0.02.
232
Cardiology Journal 2009, Vol. 16, No. 3
www.cardiologyjournal.org
hospitalization. The LDL lowering, as an acute pha-
se response to myocardial infarction, is usually as-
sociated with an increase in triglycerides and de-
crease in LDL cholesterol [18–23]. This usually
happens over several days, and the LDL-choleste-
rol does not usually decrease in the first 24 hours.
It is unlikely that this acute change is responsible
for the difference in LDL cholesterol levels in this
study because all levels were obtained within
24 hours of myocardial infarction and the size of the
infarcts was comparable by biomarkers and LV func-
tion measurement. The triglyceride levels were
also statistically comparable.
It is also possible that lower HDL in the group
with low LDL contributes to worse long-term out-
comes. Higher percentage of diabetics, hyperten-
sives, and prior myocardial infarction may also have
resulted in worse outcomes. However, multivaria-
te analysis adjusted for all the above confounding
variables was still associated with higher 3-year
all-cause mortality in patients with LDL £ 105 mg/dL.
Another clear possibility is the fact that pa-
tients with lower LDL at baseline do not get as
aggressively treated with statins. More patients
with LDL £ 105 mg/dL were on lipid lowering
therapy at baseline in this study but it is possible
that these patients did not receive such aggressive
therapy at follow-up. Since follow-up treatment data
is not available, this cannot be ruled out from the
current analysis.
In spite of this, the report that low LDL-chole-
sterol at the time of admission may be a marker for
worse long-term outcome in NSTEMI patients is
very salient. The incidence of NSTEMI is growing
and affects more than 1.5 million patients annually
in the United States [35]. Measurement of LDL
cholesterol on admission in these patients may have
significant long-term prognostic implications. Instead
of developing a false sense of security in patients
with lower LDL, these patients may in fact need
more aggressive risk modification with statins,
antiplatelet agents, beta-blockers, angiotensin
converting enzyme inhibitors, smoking cessation,
and activity modification.
Limitations of the study
The retrospective study design, selection bias,
treatment bias, and unequal distribution of baseline
co-morbidities are the major limitations of our
study. We attempted to adjust for the baseline con-
founding variables with multivariate analysis, but
may not be able to account for all confounding va-
riables and physician/treatment effects. The effect
of the myocardial infarction on the admission lipid
profile in the first 24 hours post admission is not
very well understood. Inclusion of only patients with
NSTEMI who underwent cardiac catheterization
could have limited the external validity of our fin-
dings. In addition, therapy for the groups at follow-
up was not available and its effect on outcomes is
not clear.
Conclusions
The median serum LDL cholesterol level
within the first 24 hours of admission in patients
with NSTEMI was 105 mg/dL. In our cohort, lower
LDL-cholesterol at admission was associated with
decreased three-year survival in patients with
NSTEMI. Whether this was a result of current the-
rapy or a marker for worse baseline characteristics
needs to be studied further.
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